

Know the Hidden Risks of DPD Deficiency

Urgent Need for Routine Screening in Patients Receiving Fluoropyrimidine

DPYD Testing identifies the 1 in 20 patients who are DPD Deficient. Do this before administering Fluoropyrimidine-based chemotherapies, Fluorouracil (5-FU) and Capecitabine, and you significantly reduce the risk of severe and life-threatening toxicities.

For some DPD Deficient patients, the unexpectedly severe reactions to these drugs include intense mucositis, diarrhea, neutropenia and even neurological damage. They cannot metabolize the drugs fast enough, which can lead to extended hospital stays and even death.

No One Deserves to Die of DPD Deficiency

THE HUMAN COST OF NOT TESTING



Christopher
Colon Cancer

Larry
Colon Cancer

David
Bile Duct Cancer

JoEllen
Anal Cancer

“Honestly, and simply put, it just makes sense. It’s a straightforward procedure that can save lives. While it’s rare, when it does happen, the impact is devastating. There’s no excuse for it to keep happening.”

Oncologist from a leading Massachusetts Cancer Center



ADVOCATES FOR UNIVERSAL
DPD/DPYD TESTING

Contact us: info@test4dpd.org

Advocates for Universal DPD/DPYD Testing (AUDT) aims to increase awareness of DPD deficiency, the importance of pre-screening, and the availability of DPYD testing. AUDT encourages patients, healthcare providers, and policymakers to prioritize DPYD testing to prevent avoidable suffering and save lives.

DPYD Testing:

Time to Put Patient Safety First... When Prescribing Fluoropyrimidine Chemotherapy